Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-09
2006-05-09
Caputa, Anthony C (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S308000, C424S185100
Reexamination Certificate
active
07041646
ABSTRACT:
The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
REFERENCES:
patent: 6232310 (2001-05-01), Hansen et al.
patent: 9111457 (1991-08-01), None
Adelhorst et al, 1994, Structure-activity studies of Glucagon-like Peptide-1. Journal of Biological Chemistry. 269(9): 6275-6278.
Hjorth et al, 1994, “Glucagon and Glucagon-like Peptide 1: Selective Receptor Recognition via Distinct Peptide Epitopes” Journal of Biological Chemistry, 269(48): 30121-30124.
Zander et al, Aug. 2000, “Additive Glucose-lowering effects of Glucagon-like Peptide 1 and Metformin in Type 2 Diabetes (Abstract #711)”, Diabetologia 43 (Suppl. 1): A185.
Unson et al, Multiple-site Replacement analogs of Glucagon. Journal of Biological Chemistry, 269(17): 12548-12551.
Clairmont Kevin B.
Pan Clark
Whelan James
Bayer Pharmaceuticals Corporation
Caputa Anthony C
Howard Zachary C.
Pellegrino Susan M.
LandOfFree
Methods of treating type 2 diabetes with peptides acting as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating type 2 diabetes with peptides acting as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating type 2 diabetes with peptides acting as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3633806